INFO & CONTACTS:  +39 02 2390 1

A Phase 3, Randomized, Open-label, Multicenter Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab With or Without Bevacizumab Compared With Standard of Care as Firstline Maintenance Treatment for Participants With Persistent, Recurrent, or Newly Diagnosed Metastatic Cervical Cancer With PD-L1 CPS Greater Than or Equal to 1 (TroFuse-036/GOG-3123/ENGOT-cx22)

Phase: Phase II-III clinical trials

Principal Investigator: Dott.ssa Ducceschi Monika

Main Facility: Oncologia Chirurgica Ginecologica

Drug: MK-2870, also known as Sacituzumab tirumotecan

Pathologies: Cervical tumor

Phase 3 clinical study evaluating Sacituzumab tirumotecan (MK-2870), an antibody–drug conjugate (ADC) that binds to the TROP2 protein on tumor cells, is internalized, and releases a topoisomerase I inhibitor (KL610023) that blocks DNA replication, leading to cell-cycle arrest and tumor cell death, in patients with persistent, recurrent, or newly diagnosed metastatic cervical cancer.The study includes two parts: 

an induction phase with Paclitaxel, cisplatin or carboplatin, Pembrolizumab, and Bevacizumab; 

followed by a maintenance phase with MK-2870, Pembrolizumab, and Bevacizumab. 

This is followed by an open-label, randomized 1:1 maintenance phase.

Last update: 21/04/2026

Subscribe to the newsletter

Sign up for our newsletter to stay informed about news, events, and updates from the Institute

Subscribe